mTOR and cancer: insights into a complex relationship

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216

Upstream and downstream of mTOR

Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181

TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival

Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083

mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery

Kim, D., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument‐Bromage, H., Tempst, P., & Sabatini, D. M. (2002) · Cell · doi:10.1016/s0092-8674(02)00808-5 · Cited by 3,051

Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton

Sarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665

mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt

O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561

Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB

Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

Jacinto, E., Loewith, R., Schmidt, A., Lin, S., Rüegg, M. A., Hall, A., & Hall, M. N. (2004) · Nature Cell Biology · doi:10.1038/ncb1183 · Cited by 2,097

Two TOR Complexes, Only One of which Is Rapamycin Sensitive, Have Distinct Roles in Cell Growth Control

Loewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J. L., Bonenfant, D., Oppliger, W., Jenoe, P., & Hall, M. N. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00636-6 · Cited by 1,886

Regulation of Gene Expression in Hepatic Cells by the Mammalian Target of Rapamycin (mTOR)

Jimenez, R. H., Lee, J., Francesconi, M., Castellani, G., Neretti, N., Sanders, J. A., Sedivy, J. M., & Gruppuso, P. A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009084 · Cited by 27

NVP-BEZ235, Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor, Prominently Enhances Radiosensitivity of Prostate Cancer Cell Line PC-3

Zhu, W., Fu, W., & Hu, L. (2013) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2012.1443 · Cited by 27

Compensatory Increase of Transglutaminase 2 Is Responsible for Resistance to mTOR Inhibitor Treatment

Cao, J., & Huang, W. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149388 · Cited by 27

Metformin requires 4E-BPs to induce apoptosis and repress translation of Mcl-1 in hepatocellular carcinoma cells

Bhat, M., Yanagiya, A., Graber, T. E., Razumilava, N., Bronk, S. F., Zammit, D., Zhao, Y., Zakaria, C., Metrakos, P. P., Pollak, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10671 · Cited by 27

CC-223 blocks mTORC1/C2 activation and inhibits human hepatocellular carcinoma cells in vitro and in vivo

Xie, Z., Wang, J., Liu, M., Chen, D., Qiu, C., & Sun, K. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173252 · Cited by 27

Rationale of personalized immunosuppressive medication for hepatocellular carcinoma patients after liver transplantation

Chen, K., Man, K., Metselaar, H. J., Janssen, H. L. A., Peppelenbosch, M. P., & Pan, Q. (2013) · Liver Transplantation · doi:10.1002/lt.23806 · Cited by 26

Chemotherapy for Hepatocellular Carcinoma: Current Evidence and Future Perspectives

Rinninella, E., Cerrito, L., Spinelli, I., Cintoni, M., Mele, M. C., Pompili, M., & Gasbarrini, A. (2017) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2017.00002 · Cited by 26

The preliminary radiogenomics association between MR perfusion imaging parameters and genomic biomarkers, and their predictive performance of overall survival in patients with glioblastoma

Liu, X., Mangla, R., Tian, W., Qiu, X., Li, D., Walter, K. A., EKHOLM, S. E., & Johnson, M. D. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2602-x · Cited by 26

Diabetes and its Potential Impact on Head and Neck Oncogenesis

Wang, X., Wang, H., Zhang, T., Cai, L., Dai, E., & He, J. (2019) · Journal of Cancer · doi:10.7150/jca.35607 · Cited by 26

Marine-Derived Natural Products as ATP-Competitive mTOR Kinase Inhibitors for Cancer Therapeutics

Parate, S., Kumar, V., Lee, G., Rampogu, S. D., Hong, J. C., & Lee, K. W. (2021) · Pharmaceuticals · doi:10.3390/ph14030282 · Cited by 27

Design, synthesis and biological evaluation of novel hybrids targeting mTOR and HDACs for potential treatment of hepatocellular carcinoma

Zhai, S., Zhang, H., Chen, R., Wu, J., Ai, D., Tao, S., Cai, Y., Zhang, J., & Wang, L. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113824 · Cited by 26

Novel Ubiquitin Specific Protease-13 Inhibitors Alleviate Neurodegenerative Pathology

Liu, X., Balaraman, K., Lynch, C. C., Hebron, M. L., Wolf, C., & Moussa, C. (2021) · Metabolites · doi:10.3390/metabo11090622 · Cited by 26

Engaging the Lysosome and Lysosome-Dependent Cell Death in Cancer

Berg, A. L., Rowson-Hodel, A. R., Wheeler, M. R., Hu, M., Free, S. R., & Carraway, K. L. (2022) · Exon Publications eBooks · doi:10.36255/exon-publications-breast-cancer-lysosome · Cited by 26

Detection of hepatocellular carcinoma in hepatitis C patients: Biomarker discovery by LC–MS

Bowers, J., Hughes, E. A., Skill, N. J., Maluccio, M. A., & Raftery, D. (2014) · Journal of Chromatography B · doi:10.1016/j.jchromb.2014.02.043 · Cited by 26

Sustained overexpression of Redd1 leads to Akt activation involved in cell survival

Jin, H., Hong, S., Kim, J., Choi, H.-N., Kim, K., An, S., Choe, T., Hwang, C.-S., Lee, J. H., Kim, J., et al. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.03.021 · Cited by 26

mTORC1-S6K Activation by Endotoxin Contributes to Cytokine Up-Regulation and Early Lethality in Animals

Lee, P., Wilhelmson, A. S., Hubner, A. P., Reynolds, S. B., Gallacchi, D. A., Chiou, T. T., & Kwiatkowski, D. J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014399 · Cited by 26

Therapeutic targeting of the phosphatidylinositol 3-kinase signaling pathway: novel targeted therapies and advances in the treatment of colorectal cancer

Yu, M., & Grady, W. M. (2012) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x12448456 · Cited by 26

Phosphatase and Tensin Homolog on Chromosome 10 Is Phosphorylated in Primary Effusion Lymphoma and Kaposi's Sarcoma

Roy, D., & Dittmer, D. P. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.06.017 · Cited by 26

Rictor has a pivotal role in maintaining quiescence as well as stemness of leukemia stem cells in MLL-driven leukemia

Fang, Y., Yang, Y., Hua, C., Xu, S., Zhou, M., Guo, H., Wang, N., Zhao, X., Huang, L., Yu, F., et al. (2016) · Leukemia · doi:10.1038/leu.2016.223 · Cited by 26

Clinicopathological and prognostic significance of mTOR and phosphorylated mTOR expression in patients with esophageal squamous cell carcinoma: a systematic review and meta-analysis

Li, S., Wang, Z., Huang, J. V., Cheng, S., Du, H., Che, G., & Peng, Y. (2016) · BMC Cancer · doi:10.1186/s12885-016-2940-7 · Cited by 26

Inhibition of upper small intestinal mTOR lowers plasma glucose levels by inhibiting glucose production

Waise, T. M. Z., Rasti, M., Duca, F. A., Zhang, S., Bauer, P. V., Rhodes, C. J., & Lam, T. K. T. (2019) · Nature Communications · doi:10.1038/s41467-019-08582-7 · Cited by 26

Tumor necrosis factor-alpha (TNF-α)-mediated in vitro human retinal pigment epithelial (RPE) cell migration mainly requires Akt/mTOR complex 1 (mTORC1), but not mTOR complex 2 (mTORC2) signaling

Liu, Y., Cao, G.-F., Xue, J., Wan, J., Wan, Y., Jiang, Q. Y., & Yao, J. (2012) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2012.03.008 · Cited by 26

Discrete Mechanistic Target of Rapamycin Signaling Pathways, Stem Cells, and Therapeutic Targets

Jhanwar‐Uniyal, M., Zeller, S. L., Spirollari, E., Das, M., Hanft, S. J., & Gandhi, C. D. (2024) · Cells · doi:10.3390/cells13050409 · Cited by 26

Rapamycin increases CCN2 expression of lung fibroblasts via phosphoinositide 3-kinase

Xu, X., Dai, H., Geng, J., Wan, X., Huang, X., Li, F., Jiang, D., & Wang, C. (2015) · Laboratory Investigation · doi:10.1038/labinvest.2015.68 · Cited by 25

A Novel Candidate Disease Genes Prioritization Method Based on Module Partition and Rank Fusion

Chen, X., Yan, G., & Liao, X. (2010) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2009.0143 · Cited by 25

Dysregulation of mammalian target of rapamycin pathway in upper tract urothelial carcinoma

Munari, E., Fujita, K., Faraj, S. F., Chaux, A., González-Roibón, N., Hicks, J. L., Meeker, A. K., Nonomura, N., & Netto, G. J. (2013) · Human Pathology · doi:10.1016/j.humpath.2013.07.008 · Cited by 25

Marine biogenics in sea spray aerosols interact with the mTOR signaling pathway

Asselman, J., Acker, E. V., Rijcke, M. D., Tilleman, L., Nieuwerburgh, F. V., Mees, J., Schamphelaere, K. D., & Janssen, C. (2019) · Scientific Reports · doi:10.1038/s41598-018-36866-3 · Cited by 27

Functional characterization of the PI3K/AKT/MTOR signaling pathway for targeted therapy in B-precursor acute lymphoblastic leukemia

Grüninger, P. K., Uhl, F., Herzog, H., Gentile, G., Andrade-Martinez, M., Schmidt, T., Han, K., Morgens, D. W., Bassik, M. C., Cleary, M. L., et al. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-022-00491-0 · Cited by 25

Birt–Hogg–Dubé syndrome with a renal angiomyolipoma: Further evidence of a relationship between Birt–Hogg–Dubé syndrome and tuberous sclerosis complex

Byrne, M., Mallipeddi, R., Pichert, G., & Whittaker, S. J. (2011) · Australasian Journal of Dermatology · doi:10.1111/j.1440-0960.2011.00738.x · Cited by 25

Localisation of phosphorylated mTOR expression is critical to tumour progression and outcomes in patients with endometrial cancer

Yoshida, Y., Kurokawa, T., Horiuchi, Y., Sawamura, Y., Shinagawa, A., & Kotsuji, F. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.09.004 · Cited by 25

Dual mTORC1/2 inhibition in a preclinical xenograft tumor model of endometrial cancer

Korets, S. B., Musa, F., Curtin, J. P., Blank, S. V., & Schneider, R. J. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.11.027 · Cited by 25

The PI3K-Akt pathway regulates calpain 6 expression, proliferation, and apoptosis

Liu, Y., Mei, C., Sun, L., Li, X., Liu, M., Wang, L., Li, Z., Yin, P., Zhao, C., Shi, Y., et al. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2011.01.005 · Cited by 25

A Comparison between Manual and Automated Evaluations of Tissue Microarray Patterns of Protein Expression

Alvarenga, A. W., Coutinho‐Camillo, C. M., Rodrigues, B. R., Rocha, R. M., Torres, L. F. B., Martins, V. R., da Cunha, I. W., & Hajj, G. N. M. (2013) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155413477661 · Cited by 25

Alleviating VLDL overproduction is an important mechanism for Laminaria japonica polysaccharide to inhibit atherosclerosis in LDLr−/− mice with diet‐induced insulin resistance

Zha, X., Zhang, W., Peng, F., Xue, L., Liu, J., & Luo, J. (2016) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201600456 · Cited by 25

Rapalogs can promote cancer cell stemness in vitro in a Galectin-1 and H-ras-dependent manner

Posada, I. M. D., Lectez, B. L. P., Sharma, M., Oetken-Lindholm, C., Yetukuri, L., Zhou, Y., Aittokallio, T. A., & Abankwa, D. (2017) · Oncotarget · doi:10.18632/oncotarget.17819 · Cited by 24

A new era of improving progression-free survival with dual blockade in postmenopausal HR+, HER2− advanced breast cancer

Jérusalem, G., Bachelot, T., Barrios, C. H., Neven, P., Leo, A. D., Janni, W., & BOER, R. D. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.12.011 · Cited by 24

The anti-ovarian cancer activity by WYE-132, a mTORC1/2 dual inhibitor

Zhang, D., Xia, H., Zhang, W., & Fang, B. (2015) · Tumor Biology · doi:10.1007/s13277-015-3922-0 · Cited by 24

The therapeutic value of SC66 in human renal cell carcinoma cells

Xu, M., Wang, Y., Zhou, L.-N., Xu, L., Jin, Z., Yang, D., Chen, M., & Zhu, J. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2566-1 · Cited by 24

Regulatory Role of Ubiquitin Specific Protease-13 (USP13) in Misfolded Protein Clearance in Neurodegenerative Diseases

Liu, X., & Moussa, C. (2021) · Neuroscience · doi:10.1016/j.neuroscience.2021.02.004 · Cited by 24

Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells

Jiang, S., Zou, Z., Nie, P., Wen, R., Yingying, X., & Tang, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0132880 · Cited by 24

Direct inhibition of eIF4E reduced cell growth in endometrial adenocarcinoma

Choi, C. H., Lee, J.-S., Kim, S. R., Lee, Y.-Y., Kim, C.-J., Lee, J., Kim, T., Lee, J., Kim, B., & Bae, D. (2010) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-010-0902-z · Cited by 24

Immunity and the regulation of protein synthesis: surprising connections

Pierre, P. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.03.003 · Cited by 26

CCR7 expression correlates with subcutaneous involvement in mycosis fungoides skin lesions and promotes migration of mycosis fungoides cells (MyLa) through mTOR activation

Hu, S. C., Lin, C., Hong, C., Yu, H., Chen, G., & Lee, C. (2013) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2013.12.003 · Cited by 24

A Shining Light in the Darkness for the Treatment of Pancreatic Neuroendocrine Tumors

Capdevila, J., & Tabernero, J. M. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0151 · Cited by 24

Expression of metabolically targeted biomarkers in endometrial carcinoma

Wahl, H. N., Daudi, S., Kshirsagar, M. P., Griffith, K. A., Tan, L., Rhode, J. M., & Liu, J. R. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.10.040 · Cited by 24

Autophagy inhibition sensitizes WYE-354-induced anti-colon cancer activity in vitro and in vivo

Wang, L., Zhu, Y.-R., Wang, S., & Song, Z. (2016) · Tumor Biology · doi:10.1007/s13277-016-5018-x · Cited by 24

Autophagy inhibition enhances RAD001-induced cytotoxicity in human bladder cancer cells

Lin, J., Lin, Y., Tsai, T., Chen, H., Chou, K., Hwang, T. I., & Yang, S.-C. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s95900 · Cited by 24

Combined Targeting of mTOR and Akt Using Rapamycin and MK-2206 in The Treatment of Tuberous Sclerosis Complex

Ji, S., Lin, W., Wang, L., Ni, Z., Jin, F., Zha, X., & Fei, G. (2017) · Journal of Cancer · doi:10.7150/jca.17205 · Cited by 24

CD44 variant inhibits insulin secretion in pancreatic β cells by attenuating LAT1-mediated amino acid uptake

Kobayashi, N., Okazaki, S., Sampetrean, O., Irie, J., Itoh, H., & Saya, H. (2018) · Scientific Reports · doi:10.1038/s41598-018-20973-2 · Cited by 24

Sex-specific lung diseases: effect of oestrogen on cultured cells and in animal models

Shim, B., Pacheco–Rodriguez, G., Kato, J., Darling, T. N., Vaughan, M. M., & Moss, J. (2013) · European Respiratory Review · doi:10.1183/09059180.00002813 · Cited by 24

Combination treatment with perifosine and MEK-162 demonstrates synergism against lung cancer cells in vitro and in vivo

Zhang, J., Hong, Y., & Shen, J. (2015) · Tumor Biology · doi:10.1007/s13277-015-3244-2 · Cited by 20

Mechanisms That Regulate Peripheral Immune Responses to Control Organ-Specific Autoimmunity

Hoyne, G. F. (2011) · Clinical and Developmental Immunology · doi:10.1155/2011/294968 · Cited by 24

Gremlin promotes retinal pigmentation epithelial (RPE) cell proliferation, migration and VEGF production via activating VEGFR2-Akt-mTORC2 signaling

Liu, Y., Chen, Z., Cheng, H., Chen, J., & Qian, J. (2016) · Oncotarget · doi:10.18632/oncotarget.13518 · Cited by 23

Epstein-Barr Virus LMP1-Activated mTORC1 and mTORC2 Coordinately Promote Nasopharyngeal Cancer Stem Cell Properties

Zhu, N., Wang, Q. H., Wu, Z., Wang, Y., Zeng, M., & Yuan, Y. (2022) · Journal of Virology · doi:10.1128/jvi.01941-21 · Cited by 25

War or peace: Viruses and metastasis

Bayat, M., Golestani, S., Motlaghzadeh, S., Baghi, H. B., Lalehzadeh, A., & Nahand, J. S. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189179 · Cited by 23

Mio depletion links mTOR regulation to Aurora A and Plk1 activation at mitotic centrosomes

Platani, M., Trinkle‐Mulcahy, L., Porter, M., Jeyaprakash, A. A., & Earnshaw, W. C. (2015) · The Journal of Cell Biology · doi:10.1083/jcb.201410001 · Cited by 26

High GOLPH3 expression is associated with a more aggressive behavior of epithelial ovarian carcinoma

Ma, Y., Ren, Y., Zhang, X., Lin, L. C., Liu, Y., Rong, F., Wen, W., & Li, F. (2014) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-014-1536-3 · Cited by 23

Upregulation of Ras homolog enriched in the brain (Rheb) in lipopolysaccharide-induced neuroinflammation

Cao, M., Tan, X., Jin, W., Zheng, H., Xu, W., Rui, Y., Li, L., Cao, J., Wu, X., Cui, G., et al. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2013.01.025 · Cited by 23

Structural Basis for the Association of the Redox-sensitive Target of Rapamycin FATC Domain with Membrane-mimetic Micelles

Dames, S. A. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.058404 · Cited by 25

Decreased carboxylesterases expression and hydrolytic activity in type 2 diabetic mice through Akt/mTOR/HIF-1α/Stra13 pathway

Chen, R., Wang, Y., Ning, R., Hu, J., Liu, W., Xiong, J., Wu, L., Liu, J., Hu, G., & Yang, J. (2015) · Xenobiotica · doi:10.3109/00498254.2015.1020353 · Cited by 23

A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin

Huang, Y., Xi, Q., Chen, Y., Wang, J., Peng, P., Xia, S., & Yu, S. (2013) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328363c64e · Cited by 23

Comparing mTOR inhibitor Rapamycin with Torin-2 within the RIST molecular-targeted regimen in neuroblastoma cells

Waetzig, R., Matthes, M., Leister, J., Penkivech, G., Heise, T., Corbacioglu, S., & Sommer, G. (2020) · International Journal of Medical Sciences · doi:10.7150/ijms.48393 · Cited by 23

DEPTOR ubiquitination and destruction by SCFβ-TrCP

Wang, Z. P., Zhong, J., Gao, D., Inuzuka, H., Liu, P., & Wei, W. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00105.2012 · Cited by 24

The serine 2481-autophosphorylated form of mammalian Target Of Rapamycin (mTOR) is localized to midzone and midbody in dividing cancer cells

Vázquez‐Martín, A., Oliveras‐Ferraros, C., Bernadó, L., López‐Bonet, E., & Menéndez, J. A. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.01.153 · Cited by 23

Reduction of insulin signalling pathway IRS‐1/IRS‐2/AKT/mTOR and decrease of epithelial cell proliferation in the prostate of glucocorticoid‐treated rats

Costa, M. M., Violato, N. M., Taboga, S. R., Góes, R. M., & Bosqueiro, J. R. (2012) · International Journal of Experimental Pathology · doi:10.1111/j.1365-2613.2012.00817.x · Cited by 23

Role of the Mammalian Target of Rapamycin (mTOR) Complexes in Pancreatic β-Cell Mass Regulation

Bartolomé, A., & Guillén, C. (2014) · Vitamins and hormones · doi:10.1016/b978-0-12-800174-5.00017-x · Cited by 24

Rapamycin Response in Tumorigenic and Non-Tumorigenic Hepatic Cell Lines

Jimenez, R. H., Boylan, J. M., Lee, J., Francesconi, M., Castellani, G., Sanders, J. A., & Gruppuso, P. A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007373 · Cited by 22

Validation of mammalian target of rapamycin biomarker panel in patients with clear cell renal cell carcinoma

Haddad, A., Kapur, P., Singla, N., Raman, J. D., Then, M. T., Nuhn, P., Büchner, A., Bastian, P. J., Seitz, C., Shariat, S. F., et al. (2014) · Cancer · doi:10.1002/cncr.28976 · Cited by 22

Concurrent inhibition of mTORC1 and mTORC2 by WYE-687 inhibits renal cell carcinoma cell growth in vitro and in vivo

Pan, X., Gu, D., Mao, J., Zhu, H., Chen, X., Zheng, B., & Shan, Y. (2017) · PLoS ONE · doi:10.1371/journal.pone.0172555 · Cited by 22

Prolactin and Growth Hormone Signaling and Interlink Focused on the Mammosomatotroph Paradigm: A Comprehensive Review of the Literature

Castro, M. A., Marazuela, M., Puig‐Domingo, M., & Biagetti, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814002 · Cited by 23

Ser2481-autophosphorylated mTOR colocalizes with chromosomal passenger proteins during mammalian cell cytokinesis

Vázquez‐Martín, A., Saurí, T., Menendez, O. J., Oliveras‐Ferraros, C., Cufí, S., Corominas-Faja, B., López‐Bonet, E., & Menéndez, J. A. (2012) · Cell Cycle · doi:10.4161/cc.22551 · Cited by 22

Trilayer micelles for combination delivery of rapamycin and siRNA targeting Y-box binding protein-1 (siYB-1)

Zeng, S., & Xiong, M. P. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.05.010 · Cited by 22

Everolimus in the treatment of patients with advanced pancreatic neuroendocrine tumors: latest findings and interpretations

Liu, E. V., Marincola, P., & Öberg, K. (2013) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x13496970 · Cited by 22

FXR blocks the growth of liver cancer cells through inhibiting mTOR-s6K pathway

Huang, X., Zeng, Y., Wang, X., Ma, X., Li, Q., Li, N., Su, H., & Huang, W. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.04.106 · Cited by 22

Regulation of anti-apoptotic Bcl-2 family protein Mcl-1 by S6 kinase 2

Basu, A., & Sridharan, S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173854 · Cited by 24

Highly Selective, Potent, and Oral mTOR Inhibitor for Treatment of Cancer as Autophagy Inducer

Guo, Q., Yu, C., Zhang, C., Li, Y., Wang, T., Huang, Z. L., Wang, X., Zhou, W., Li, Y., Qin, Z., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01402 · Cited by 22

UVB-induced inactivation of manganese-containing superoxide dismutase promotes mitophagy via ROS-mediated mTORC2 pathway activation

Dhar, S. K., Batinic̈‐Haberle, I., & Clair, D. K. S. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.006595 · Cited by 22

Complement factor H‑related 3 overexpression affects hepatocellular carcinoma proliferation and apoptosis

Liu, H., Zhang, L., & Wang, P. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10514 · Cited by 22

Interaction of polyamines and mTOR signaling in the synthesis of antizyme (AZ)

Ray, R. M., Bavaria, M. N., & Johnson, L. R. (2015) · Cellular Signalling · doi:10.1016/j.cellsig.2015.06.002 · Cited by 22

ITD‐ and FL‐induced FLT3 signal transduction leads to increased C/EBPβ‐LIP expression and LIP/LAP ratio by different signalling modules

Haas, S. C., Huber, R., Gutsch, R., Kandemir, J. D., Cappello, C., Krauter, J., Duyster, J., Ganser, A., & Brand, K. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.08012.x · Cited by 22

The short chain cell-permeable ceramide (C6) restores cell apoptosis and perifosine sensitivity in cultured glioblastoma cells

Li-Sen, Q., Yu, Z., Zhang, S.-M., Sun, G., Zhu, J. S., Xu, J., Guo, J. X., & Fu, L. (2013) · Molecular Biology Reports · doi:10.1007/s11033-013-2666-4 · Cited by 21

Overexpression of pyruvate dehydrogenase phosphatase 1 promotes the progression of pancreatic adenocarcinoma by regulating energy-related AMPK/mTOR signaling

Li, Y., Shen, J., Cheng, C., Gao, H., Zhao, J., & Chen, L. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-00457-5 · Cited by 21

PTEN Blocking Stimulates Corticospinal and Raphespinal Axonal Regeneration and Promotes Functional Recovery After Spinal Cord Injury

Bhowmick, S., & Muneer, P. M. A. (2020) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlaa147 · Cited by 21

Non-invasive imaging of PI3K/Akt/mTOR signalling in cancer.

Gaikwad, S. M., & Ray, P. (2012) · Europe PMC (PubMed Central) · Cited by 21

The anti-esophageal cancer cell activity by a novel tyrosine/phosphoinositide kinase inhibitor PP121

Peng, Y., Zhou, Y., Cheng, L., Hu, D., Zhou, X., Wang, Z., Xie, C., & Zhou, F. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.07.147 · Cited by 21

DNA-PKcs interference sensitizes colorectal cancer cells to a mTOR kinase inhibitor WAY-600

Wu, L., Zhang, J., Wu, H., & Han, E.-K. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.09.068 · Cited by 21

Genetics and genomics of childhood adrenocortical tumors

Wakil, A. E., Doghman, M., de Laté, P. L., Zambetti, G. P., de Figueiredo, B. C., & Lalli, E. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.11.008 · Cited by 21

Calcineurin A-β is required for hypertrophy but not matrix expansion in the diabetic kidney

Reddy, R. N., Knotts, T., Roberts, B. R., Molkentin, J. D., Price, S. R., & Gooch, J. L. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00910.x · Cited by 21

The chemokine CXCL9 exacerbates chemotherapy-induced acute intestinal damage through inhibition of mucosal restitution

Lu, H., Liu, H., Wang, J., Shen, J., Weng, S., Han, L., Sun, T., Qian, L., Wu, M., Zhu, S., et al. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1869-y · Cited by 21

Targeting Endocrine Resistance: Is There a Role for mTOR Inhibition?

Sheri, A., Martin, L., & Johnston, S. R. D. (2010) · Clinical Breast Cancer · doi:10.3816/cbc.2010.s.016 · Cited by 21

Prognostic role of phospho-PRAS40 (Thr246) expression in gastric cancer

Lu, Y., Deng, A., Li, L.-H., Liu, G., & Wu, G. (2013) · Archives of Medical Science · doi:10.5114/aoms.2013.36927 · Cited by 21

Endocrine resistance in breast cancer

Zheng, L.-L., Zhao, Y., Feng, H., & Liu, Y. J. (2013) · Climacteric · doi:10.3109/13697137.2013.864268 · Cited by 21

Involvement of mTOR signaling pathways in regulating growth and dissemination of metastatic brain tumors via EMT.

Kwasnicki, A. M., Jeevan, D. S., Braun, A., Murali, R., & Jhanwar‐Uniyal, M. (2015) · PubMed · Cited by 21

Node-based learning of differential networks from multi-platform gene expression data

Ou-Yang, L., Zhang, X.-F., Wu, M., & Li, X. (2017) · Methods · doi:10.1016/j.ymeth.2017.05.014 · Cited by 21

Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib

Osoegawa, A., Gills, J. J., Kawabata, S., & Dennis, P. A. (2017) · Oncotarget · doi:10.18632/oncotarget.19667 · Cited by 21

Biallelic TSC2 Mutations in a Patient With Chromophobe Renal Cell Carcinoma Showing Extraordinary Response to Temsirolimus

Maroto, P., Anguera, G., Roldán‐Romero, J. M., Apellániz-Ruiz, M., Ferran Algaba, B., Boonman, J., Nellist, M. D., Montero‐Conde, C., Cascón, A., Robledo, M., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.7041 · Cited by 21

Nitidine Chloride Inhibits SIN1 Expression in Osteosarcoma Cells

Xu, H., Cao, T., Zhang, X., Shi, Y., Zhang, Q., Chai, S., Li, Y., Jin, G., Ma, J., Wang, Z. P., et al. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.01.005 · Cited by 21

A phase II study of everolimus in patients with advanced solid malignancies with TSC1, TSC2, NF1, NF2 or STK11 mutations

Devarakonda, S. H. K., Pellini, B., Verghese, L., Park, H., Morgensztern, D., Govindan, R., Suresh, R., Oppelt, P., Baggstrom, M. Q., Wu, N., et al. (2021) · Journal of Thoracic Disease · doi:10.21037/jtd-21-195 · Cited by 20

Knockdown of anion exchanger 2 suppressed the growth of ovarian cancer cells via mTOR/p70S6K1 signaling

Zhang, L.-J., Lu, R., Song, Y.-N., Zhu, J., Xia, W., Zhang, M., Shao, Z.-Y., Huang, Y., Zhou, Y., Zhang, H., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-06472-w · Cited by 22

Next generation of mammalian target of rapamycin inhibitors for the treatment of cancer

Nelson, V. M., Altman, J. K., & Platanias, L. C. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.787066 · Cited by 20

Drug discovery targeting the mTOR pathway

Martelli, A. M., Buontempo, F., & McCubrey, J. A. (2018) · Clinical Science · doi:10.1042/cs20171158 · Cited by 77

TOR (target of rapamycin) as an anti-cancer target

Bousquet, G., Dreyer, C., Faivre, S. J., & Raymond, É. (2007) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2008.04.004 · Cited by 2

Mammalian Target of Rapamycin (mTOR) Signalling Pathway-A Potential Target for Cancer Intervention: A Short Overview

Basnet, R., Basnet, B. B., Gupta, R., Basnet, T. B., Khadka, S., & Alam, M. S. (2023) · Current Molecular Pharmacology · doi:10.2174/1874467217666230331081959 · Cited by 11

Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy

Wander, S. A., Hennessy, B. T., & Slingerland, J. M. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44145 · Cited by 427

Unveiling the Role of Mechanistic Target of Rapamycin Kinase (MTOR) Signaling in Cancer Progression and the Emergence of MTOR Inhibitors as Therapeutic Strategies

Mehta, D., Rajput, K., Jain, D., Bajaj, A., & Dasgupta, U. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00530 · Cited by 25